• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JULY 29, 2000

Knoll Pharma: A strong dose

A 30% growth in earnings on a 13.6% growth in the topline is a strong enough dose but Knoll has during the quarter also sold units of mutual funds which have realised an extraordinary profit of Rs 160.5 m.

(Rs m) 2QFY99 2QFY00 Change
Sales 790 897 13.6%
Other Income 18 30 64.5%
Expenditure 688 763 10.9%
Operating Profit (EBDIT) 102 134 31.4%
Operating Profit Margin (%) 12.9% 14.9%  
Interest 1 7  
Depreciation 14 14 6.7%
Profit before Tax 106 143 35.2%
Other Adjustments   161  
Tax 20 30  
Profit after Tax/(Loss) 86 273 217.5%
Net profit margin (%) 10.9% 12.6%  
No. of Shares (m) (eoy) 16.2 16.2  
Diluted no. of shares (m) 16.2 16.2  
Diluted Earnings per share* 21.3 67.5  
*(annualised)      

The company is a leading player in the anti–diabetes, pain control and antacid market with brands such as Brufen, Digene, Epilex (anti–epilepsy) and Cremmafin (laxative) market.

During the quarter the company has entered into an agreement with Kalpataru Homes for the part development of its Sion premises for a consideration of Rs 140 m.

The stock quotes at a price of Rs 314 (near its 52 week low of Rs 300) which implies an earning multiple of 4.6 times the second quarter annualised earnings.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407